// App-Quantinova.ai

P-144 : Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial

Researchers

Presenter

  • G. Abou-Alfa

Principal Investigators

  • I. Borbath

  • A. Cohn

  • L. Goyal

  • A. Lamarca

  • T. Macarulla

  • D. Oh

  • S. Roychowdhury

  • S. Sadeghi

  • R. Shroff

  • M. Howland

  • A. Li

  • T. Cho

  • A. Pande

  • M. Javle

Medical Centers

  • Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY

  • Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium

  • Rocky Mountain Cancer Centers,Aurora,Vereinigte Staaten

  • Massachusetts General Hospital, Boston, MA, United States

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • CLIA Cancer Genomics Laboratory, Comprehensive Cancer Center and The James Cancer Hospital at The Ohio State University, Columbus, United States

  • David Geffen School of Medicine at UCLA, Santa Monica, California

  • The University of Arizona Cancer Center,Tuscon,United States

  • QED Therapeutics Inc., San Francisco, United States

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Locations

  • United States

  • Belgium

  • United Kingdom

  • Spain

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • Fibroblast Growth Factor Receptor 2

Drug/Treatment

  • Infigratinib

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Cross Over

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved